Adenocarcinoma is defined as tumors that occur in tissues of glandular origins or characteristics. Prevalent types of adenocarcinomas include lung adenocarcinoma (LUAD), prostate adenocarcinoma (PRAD), as well as colon and rectal adenocarcinoma (CRAD). TCGA and other studies has conducted molecular profiling study of LUAD [1] and CRAD [2, 3] separately, and discovered the genomic and epigenetic aberrations that may have driven each cancer type. These studies identified distinct methylation subtypes within each cancer type and found hypermethylation signatures within some samples. For example, a subset of both colon and rectal cancers were hyper-methylated and was characterized as CpG island methylator phenotype-high (CIMP-H) and the other subset as CIMP-low (CIMP-L), with CIMP-H tumors showing hypermutation in MLH1. In lung cancer, there were largely three subsets, CIMP-H, CIMP-L and the other intermediate group.
CIMP-H lung tumors showed DNA hypermethylation in CD-KN2A, GATA2, GATA4 among other genes. Methylation and epigenetic regulation of cancer genes are considered to largely contribute to tumorigenesis, and identifying these key events would advance our understanding of tumor etiology [4] .
Despite the known signatures in each cancer type, it is unclear whether different types of adenocarcinoma share defining epigenetic signature. Shared signatures within adenocarcinoma would be of great interest, as they present opportunities to develop therapies that may be applied to treat multiple cancer types. The pan-cancer initiative of TCGA aims to gain additional insights from jointly analyzing tumor profiles from different cancer types, and has resulted in many fruitful genomic findings [5] . However, relatively few studies have investigated methylation at a pan-cancer level. By reviewing methylomes across cancer types from singletumor-type studies, Witte et al. [6] pinpointed some shared and distinct methylation signatures between cancer types.
Recently, Gevaert et al. [7] developed MethylMix and evaluated differentially methylated genes across 12 cancer types. They identified 10 major clusters through the pan-cancer analysis, and suggested there may be similar epigenetic regulation on certain cancer types.
DNA methylation is highly involved in developmental processes and has been widely established to be dependent on tissue types and origins [8] . However, to our knowledge, no TCGA pan-cancer studies have combined and examined methylome according to their tissue similarities. In this study, we hypothesized that different types of adenocarcinoma may share methylation patterns that drive tumorigenesis. We conducted a comprehensive analysis on three types of common adenocarcinoma in the TCGA: LUAD, PRAD and CRAD. We identified enrichment of likely epigenetic silenced genes in developmental processes and the WNT signaling pathway, and dissected the epigenetic regulation landscape in associated WNT pathway genes across samples from different types of adenocarcinomas.
Materials and methods
Samples and methylation, RNA expression data. Level 3 DNA methylation data of LUAD (451), CRAD (393) and PRAD (498) was downloaded from The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov/). We extracted the methylation β-value as methylation level for downstream analysis.
Processed mRNA-seq data of LUAD (451), CRAD (370) and PRAD (498) was downloaded from the same source. RPKM (Reads Per Kilobase per Million mapped reads) values that quantify at the gene level were calculated for further analysis in the R 2.15 environment. RPKM for a given Gene1 is calculated by: (raw read counts × 10 9 ) / (total reads × length of Gene1). We used gene level read counts to calculate RPKM.
421 LUAD, 314 CRAD, and 479 PRAD samples, or a total of 1214 adenocarcinoma samples, have both DNA methylation and expression data and were used in the final analysis. We merged colon and rectal adenocarcinomas into one group, CRAD, as molecular profiles of these two showed no distinguishing difference [3] .
Candidate functional CpG sites and epigenetically silenced genes. We determined candidate functional CpG sites and epigenetically silenced genes in all three cancer types by adopting a previously developed strategy [9] .The methylation status of CpG site and its associated gene's expression level is evaluated jointly. We defined four criteria each with a relaxed threshold and a stringent threshold. We required candidate epigenetically silenced genes to pass all 4 relaxed thresholds, and at least 3 out of 4 stringent thresholds: (1) The mean DNA methylation β-value in non-tumor adjacent colonic tissue < 0.5 (relaxed) and < 0.4 (stringent); (2) The difference in DNA methylation β-value between the 90th percentile tumor and mean adjacent-normal > 0.1 (relaxed) and > 0.3 (stringent); (3) The fold expression change between mean adjacent-normal and mean of the 10% of tumor samples with the highest DNA methylation > 1.5 (relaxed) and > 3 (stringent); (4) Spearman's correlation coefficient between DNA methylation and gene expression calculated jointly across tumor and adjacent-normal tissue samples < -0.2 (relaxed) and < -0.3 (stringent).
Location analysis. CpG islands, RefSeq gene coding loci feature were all downloaded from the UCSC Genome Browser (https://genome.ucsc.edu/), and introns, exons were defined according to the coordinates. We defined the promoter region as 500bp upstream of transcription start site to 500bp downstream of transcription start site.
Enrichment analysis. Enrichment of biological processes was evaluated through the Gene Ontology website (http:// geneontology.org). We retained all biological processes where the enrichment FDR is below 0.01. Enrichment of biological pathways was determined through the InnateDB Pathway Analysis (http://www.innatedb.ca/index.jsp). We used the Chi Square test and Bonferroni p-value correction. We retained all pathways where the enrichment FDR is below 0.01.
Genome browser data assembly. We calculated the mean methylation value of samples in each cancer type, and then upload these to WashU Epigenome Browser (http://epigenomegateway.wustl.edu/) and captured in the methylation values in the display track.
Clustering of epigenetically silenced genes in the WNT pathway. We assessed the DNA methylation and mRNA expression of each candidate epigenetically silenced genes in the WNT signaling pathway in each sample. Then we picked the probes with the highest absolute Spearman's Rho to assess the methylation level of the chosen gene. We conducted k-means clustering (K=2) based on the two-dimensional space of DNA methylation and gene expression data to classify the epigenetically silenced group and non-epigenetically silenced group of sample. Then, according to the gene silencing status, we performed hierarchical clustering to find samples and WNT pathway genes with similar epigenetic regulation profiles.
Statistical analysis. All analysis on candidate functional CpG sites and epigenetically silenced genes were conducted in the R 2.15 environment. Enrichment tests were conducted through web implementations of Gene Ontology Analysis (http://geneontology.org) and InnateDB Pathway Analysis (http://www.innatedb.ca/index.jsp).
Results
Candidate epigenetically silenced genes and functional CpG sites shared across all three types of adenocarcinomas. Through analyzing methylation and RNA expression data with pre-defined criteria (see Material and Methods), we identified 1752, 2246, and 2621 candidate epigenetically silenced genes in LUAD, CRAD and PRAD, respectively ( Figure 1C ). These genes exhibited high levels of methylation that correlated with low mRNA expressions. 602 of these genes were shared between all 3 cancer types, suggesting a sizable extent of similarity between epigenetic regulation in adenocarcinoma (Supplemental table 1 ).
Then we identified 2371, 3076, and 2488 candidate functional CpG sites associated with the candidate epigenetically silenced genes in LUAD, CRAD and PRAD, respectively (Figure 1A and Supplemental table 2 ). Most of the candidate functional CpG sites resided in CpG islands. Promoter, exon, and intron regions each harbor around 15% to 20% of these sites, and the distributions between these three cancer types were consistent ( Figure 1B ). This indicated that CpG sites in gene regions other than the promoter could also regulate gene expression. Additionally, this analysis confirmed that we are not observing batch effect in individual cancer type, and gave us confidence to pursue further analysis on the shared epigenetically silenced gene set.
Enrichment analyses of candidate epigenetically silenced genes. Through gene ontology analysis, the 602 candidate epigenetically silenced genes were found to be enriched in multiple development-related biological processes ( Figure  1D ). The top enriched processes include system development, multicellular organismal development, and anatomical structure development. This indicated that the genes in these developmental programs were likely suppressed through epigenetic regulation in adenocarcinomas.
Then we conducted pathway enrichment analysis and found the 602 genes to be enriched in the KEGG basal cell carcinoma pathway (p=7.58x10 -7 ) and WNT signaling pathway (p=1.53x10 -6 ) at FDR levels lower than 1x10 -3 (Supplemental  table 3 ). Basal cell carcinoma involved mis-regulation of the WNT signaling pathway, and those that were present in the WNT signaling pathway largely account for the enrichment of 602 genes in the basal cell carcinoma pathway. This suggested that epigenetic silencing of the WNT pathway components may contribute to adenocarcinomas. Interestingly, the epigenetically repressed genes include WNT pathway activators, such as WNT3A, WNT10A, AXIN2, as well as negative regulators, such as KDD1, SFRP1, and WIF1 (Figure 2 ). While the methylation and expression of the WNT pathway genes were largely mis-regulated in adenocarcinomas, the mechanism may not be a uniform activation or repression of the pathway in all tumors.
Functional CpG sites and methylation levels in epigenetically silenced genes. While the candidate epigenetically silenced genes overlapped between three types of adenocarcinomas, it was unclear whether the candidate functional CpG sites and the pattern of methylation across these genes would be consistent across all three tumor-types. Specifically, we examined methylation patterns of three WNT pathway genes that showed similar or different extent of epigenetic silencing across cancer types (Supplemental table 4): PRKCB (epigenetically-silenced in 75.8% of LUAD, 85.6% of PRAD, and 93.6% of COAD samples), NKD1 (epigenetically-silenced in 99.8% of LUAD, 99.8% of PRAD, and 84.7% of COAD samples), and FZD10 (epigenetically-silenced in 97.2% of LUAD, 80.0% of PRAD, and 95.9% of COAD samples). We focused on the promoter region, and examined methylation levels at sites that are within -3kb to +3kb of the transcription start site (TSS).
Each gene showed different extents of shared methylation and functional CpG site profiles across 3 cancer types (Figure 3 ). In the promoter region of PRKCB, there were consistently multiple adjacent CpG sites where the level of methylation in tumor was higher than that in adjacent normal tissue. And the candidate functional CpG site (shaded in yellow) was consistent across LUAD, PRAD, CRAD and their corresponding controls. For NKD1, there was only one obvious differentially methylated CpG site that was also determined to be a candidate functional site. Like PRKCB, the pattern of this site was also consistent across three tumor types. In FZD10, interestingly, the methylation patterns varied across tumor types. LUAD and CRAD shared multiple candidate functional CpG sites that were not significantly differentially methylated in PRAD upstream of TSS. Thus, while the candidate epigenetically silenced genes may be shared in three adenocarcinomas, the likely functional CpG sites and underlying epigenetic regulation may still be different depending on the tumor type.
Patient-specific methylation and expression signatures in genes of the WNT signaling pathway. In addition to crosstumor type differences, we were interested in whether there would be differences in methylation and epigenetic regulation of the WNT signaling pathway between different samples of the same tissue type. We conducted a k-means (k=2) clustering on the two-dimensional space of DNA methylation and gene expression to define whether each WNT pathway gene was epigenetically repressed or expressed in each sample. Then, we carried out hierarchical clustering to determine which samples and genes showed similar epigenetic regulation signatures.
Interestingly, the samples did not cluster solely based on tumor type (Figure 4) . Each tumor type contained a fraction of samples showing strong epigenetic silencing in all of the WNT pathway genes, and other fractions of samples expressing subset of the WNT pathway genes. This was consistent with TCGA's previous single-tumor type study on LUAD [1] and CRAD [3] where a CIMP-H and a CIMP-L groups were defined. Our result not only validated this finding in the WNT signaling pathway, but also demonstrated that CIMP-H tumors may resemble CIMP-H tumors of different adenocarcinomas to a higher extent than they resemble CIMP-L tumors of the same tumor type. The samples that expressed a subset of the WNT pathway genes showed varied combination of epigenetic silencing and expression across WNT pathway genes. Thus, the epigenetic regulation of each of these adenocarcinomas may be different.
On the gene level, each of the WNT pathway genes displayed different methylation profiles across samples (Figure 4 ). Of note, we identified a cluster of genes---including DKK1, WIF1, and NKD1---that were epigenetically silenced in almost all adenocarcinomas. These three genes were all negative regulators of the WNT signaling pathway (Figure 2 ), implicating repressing the negative regulation of the WNT pathway may contribute to adenocarcinoma. However, multiple key activating components of the WNT signaling pathway were also significantly repressed in many samples. Epigenetic regulation of the WNT pathway genes may be complex and patient-specific.
Discussion
While methylation has been investigated in cohorts of single or several tumor types [7] , methylation in tissues of common developmental origins, such as the glandular tissues, have not been examined globally. To our knowledge, this is the first study to systematically evaluate the methylation and epigenetic silencing landscape across multiple types of adenocarcinoma. We successfully identified 602 epigenetically silenced genes in adenocarcinoma through analyzing methylation and mRNA expression data across 1214 samples of LUAD, PRAD, and CRAD ( Figure 1A ). These genes were significantly enriched in developmental processes ( Figure 1D ), implicating the importance of epigenetic repression of certain developmental programs in tumorigenesis. While somatic mutations have been widely considered as main drivers of tumors, amounting evidence has suggested that tumorigenesis is largely affected by surrounding environments and driven by aberrant epigenetic regulation during development [10, 11] Our results provided supporting evidence that epigenetic aberration in development may be associated with adenocarcinoma.
The WNT signaling pathway is essential in development and controls cell growth and survival [12] . Previous studies have shown that mutations or mis-regulation of WNT pathway genes may contribute to tumorigenesis in multiple cancer types [13, 14, 15] . We identified WNT pathway as one of the most enriched pathways for our candidate epigenetically silenced genes; out of the 602 genes we identified, 15 genes were in the WNT pathway (Supplemental table 3 , enrichment test p-value=1.53 x10 -6 ). Some of these genes, including SFRP1, SOX17 and WIF1, have previously been shown to be epigenetically silenced in LUAD [1] . Our result suggested that epigenetic silencing of these genes might not be limited to LUAD, but common to multiple adenocarcinomas.
Beyond what previous studies have found, we identified both activating components and negative regulators of the WNT pathway that were epigenetically silenced in adenocarcinoma (Figure 2) , indicating that the pathway was neither uniformly activated nor suppressed in tumors. Cancer stem cells (CSC) are thought to drive tumorigenesis and progression. They have the ability to cell-renew and give rise to malignant tumor cells [16] CSCs may require an intricate balance in the WNT pathway activity: on the one hand, they may require WNT activation to trigger self-renewal [17] ; on the other hand, they may need to inhibit WNT pathway to suppress developmental processes to retain their stem-cell state [18] . This could potentially explain why we observed methylation and epigenetic silencing in known WNT inhibitors, such as SFRP1, WIF1, and DKK1, as well as WNT activating components, such as WNT3A, FZD10, and PRKCB, in adenocarcinomas.
Since CSCs play a crucial role in tumor expansion, cancer treatments suppressing CSCs could potentially deter tumor relapse and metastasis. Multiple therapeutic strategies targeting the WNT signaling pathway in CSCs are under active development [19, 20] . Given the differences in the epigenetic profiles of the WNT pathway genes between samples ( Figure  4 ), it will be important to examine methylation of key targeted genes before devising treatment. Hierarchical clustering of methylation and expression of WNT pathway genes showed that each of the tumor types had a CIMP-H and CIMP-L cluster. This is consistent with earlier TCGA finding in LUAD [1] and CRAD [3] . Additionally, our clustering analysis showed that CIMP-H samples of different cancer types may be more similar to each other than CIMP-L samples of the same cancer type. Thus, WNT-targeting treatments that were developed for CIMP-H samples of a certain adenocarcinoma may also be applied to CIMP-H samples of another adenocarcinoma. Overall, while this study provides strong evidence showing that aberrant methylation and epigenetic regulation of the WNT signaling pathway genes associate with adenocarcinomas, the detailed mechanisms still require further elucidation. The functional consequences of these epigenetic changes would also need to be experimentally validated before this knowledge can be applied to developing WNT-targeting therapies in adenocarcinoma.
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